SCREENING FEE Sample Clauses
The SCREENING FEE clause establishes a charge that an applicant must pay to cover the costs associated with processing and evaluating their application, typically for rental housing. This fee is generally non-refundable and is used to offset expenses such as background checks, credit reports, and administrative time spent by the landlord or property manager. By requiring a screening fee, the clause ensures that only serious applicants apply and that the landlord can recover costs incurred during the tenant selection process.
POPULAR SAMPLE Copied 3 times
SCREENING FEE. Daiichi shall pay to Anadys a nonrefundable-screening fee of Four Hundred Thousand United States Dollars (US $400,000) within twenty-one (21) days after the Effective Date.
SCREENING FEE. With EACH Screening Request made by Taisho under Section 6.1 of this Agreement, Taisho shall simultaneously provide to Arena a Screening Fee of [*************************** (*******)]. Upon receipt of such Screening Fee, the following shall apply:
(a) For EACH Taisho Activated Receptor and its corresponding Screening Assay, Arena, using Best Reasonable Commercial Efforts, shall utilize the Taisho Activated Receptor and the Screening Assay for Screening using Arena Library Compounds ("Arena Screening").
(b) For EACH Taisho Activated Receptor subject to Arena Screening, Arena shall use Best Reasonable Commercial Efforts to identify at least [*** (**)] CART Identified Compound.
(c) The Parties acknowledge and understand that once made, EACH Screening Fee shall be non-refundable and non-creditable, and that the maximum amount that Taisho would be required to pay to Arena under this Section 6.2 is [************************ (*******)] in the event that Taisho provides [**** (**)] Screening Requests to Arena.
SCREENING FEE. Mitsubishi will pay NeoGenesis a screening fee of [*] for the NeoGenesis services pursuant to the Program. Mitsubishi will pay this fee within thirty (30) days of the Effective Date. *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
SCREENING FEE. Tularik shall pay NeoGenesis a fee of [*] for each Screening Target screened pursuant to the Screening Program. Such fee shall be payable in two (2) installments - the first installment of [*] at the time such Screening Target is delivered to NeoGenesis and the second installment of [*] within [*] of Completion of Screening; provided, however, that the amount of the second installment shall be reduced for a particular Screening Target by [*] if Completion of Screening does not occur within [*] following delivery of such Screening Target to NeoGenesis. COMPLETION OF SCREENING shall be deemed to occur upon delivery of Selected Screening Compounds for a Screening Target to Tularik (or, if Tularik does not designate any Selected Screening Compound(s) for such Screening Target within [*] of receipt of the Final Target Report for such Screening Target, including any supplement thereto as described in Paragraph 7 of ATTACHMENT A, then at the end of such [*] period). No payment shall be due NeoGenesis under this Section 4.2 with respect to Shared Targets.
SCREENING FEE. CUSTOMER will pay NeoGenesis a screening fee of [*] per accepted Target for the NeoGenesis services pursuant to the Program with respect to such Target. CUSTOMER will pay this fee within [*] of the effective date of a designated Target being accepted by NeoGenesis. In addition, CUSTOMER will pay NeoGenesis a fee of [*] per Target in FTE funding for the Program ([*] people for [*] at an FTE of [*]). Such FTE funding shall be paid at the commencement of each Program. Any additional FTE funding for a Target (for Program services beyond those specified in paragraphs 1-7 and 9 of ATTACHMENT A (i.e., optimization of three Selected Compounds to a Kd value of [*] and [*] of optimization on [*] Selected Compounds) must be approved by the Steering Committee on a Target-by-Target basis and will be charged at the rate of [*] per FTE. In addition to the fees described above, at the completion of each Program CUSTOMER shall pay to NeoGenesis a fee of [*].
SCREENING FEE. With each Screening Request made by Taisho under Section 6.1 of this Agreement, Taisho shall simultaneously provide to Arena a Screening Fee of [******************************************]. Upon receipt of such Screening Fee, the following shall apply:
(a) For each Taisho Activated Receptor and its corresponding Screening Assay, Arena, using Best Reasonable Commercial Efforts, shall utilize the Taisho Activated Receptor and the Screening Assay for Screening using Arena Library Compounds ("Arena Screening").
(b) For each Taisho Activated Receptor subject to Arena Screening, Arena shall use Best Reasonable Commercial Efforts to identify at least [*******] CART Identified Compound.
SCREENING FEE. Aventis shall pay NeoGenesis a fee of [*] for each Screening Target screened pursuant to the Program that is a non-protein/protein interaction Screening Target and a fee of [*] for each Screening Target screened pursuant to the Program that is a protein/protein interaction Screening Target. Such fee shall be payable with respect to the first [*] Screening Targets in two installments: the first installment of [*] on the Effective Date and the second installment consisting of the remaining balance due in accordance with the immediately preceding sentence within [*] of "completion of screening" against all [*] of the Screening Targets. "Completion of screening" for each Screening Target shall be deemed to occur upon delivery of Hit Compounds for such Screening Target to Aventis (or, if Aventis does not designate any Hit Compound(s) for such Screening Target, within [*] of receipt of the Final Target Report for such Screening Target, then at the end of such [*] period). Any work conducted for further optimization and evaluation of Hit Compounds to Selected Series or to Lead Compounds will be carried out on FTE basis in accordance with Section 4.2 and Paragraphs 7-8 of ATTACHMENT A.